2m 2m 2m 2m 2m 2m 2m
MAXCYTE (MXCT)
NASDAQ
$1.20-$0.03 (-2.52%)
Price as of Jun 03, 2026 6:44 PM EDT- $129.6MMarket Cap
- -46.05%1-Year Change
- Medical DevicesIndustry
MAXCYTE (MXCT)
$1.20-$0.03 (-2.52%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 33.0M -14.50% | 38.6M -6.44% | 41.3M -6.72% | 44.3M +30.59% | |
Cost of Revenue | 6.2M -12.37% | 7.1M +49.73% | 4.7M -6.99% | 5.1M +39.78% | |
Gross Profit | 26.8M -14.98% | 31.5M -13.73% | 36.5M -6.68% | 39.2M +29.48% | |
Sales and Marketing Expense | 18.9M -29.02% | 26.7M -1.16% | 27.0M +44.62% | 18.7M +43.45% | |
Research and Development Expense | -20.8M -6.32% | -22.2M -6.68% | -23.8M +22.05% | -19.5M +26.66% | |
Depreciation and Amortization Expense | 4.3M +0.58% | 4.3M +3.45% | 4.2M +54.60% | 2.7M +89.47% | |
Total Operating Expenses | 78.7M -4.86% | 82.7M -2.50% | 84.8M +27.54% | 66.5M +37.35% | |
Operating Profit | -51.9M +1.37% | -51.2M +6.00% | -48.3M +76.53% | -27.4M +50.43% | |
Interest Income | 7.3M -28.35% | 10.1M -2.26% | 10.4M +164.92% | 3.9M +2,497.21% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | -5,400 0.00% | |
Interest Income and Expense and Net | 7.3M -28.35% | 10.1M -2.26% | 10.4M +165.29% | 3.9M +2,589.96% | |
Total Nonoperating Income and Expense | 7.3M -28.35% | 10.1M -2.26% | 10.4M +173.79% | 3.8M +524.09% | |
Income before Taxes | -44.6M +8.71% | -41.1M -15.00% | -48.3M +76.53% | -27.4M +50.43% | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -44.6M +8.71% | -41.1M +8.26% | -37.9M +60.89% | -23.6M +23.52% | |
Net Income from Continuing Operations Applicable to Common | -44.6M +8.71% | -41.1M +8.26% | -37.9M +60.89% | -23.6M +23.52% | |
Basic EPS and Net Income | -0.42 +7.69% | -0.39 +5.41% | -0.37 +60.87% | -0.23 +9.52% | |
Diluted EPS and Net Income | -0.42 +7.69% | -0.39 +5.41% | -0.37 +60.87% | -0.23 +9.52% | |
Basic Weighted Average Shares | 106.4M +1.51% | 104.8M +1.53% | 103.3M +1.54% | 101.7M +12.23% | |
Diluted Weighted Average Shares | 106.4M +1.51% | 104.8M +1.53% | 103.3M +1.54% | 101.7M +12.23% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 20.1M -28.04% | 27.9M -40.04% | 46.5M +320.31% | 11.1M -76.84% | |
Short-Term Investments | 83.0M -34.45% | 126.6M +3.95% | 121.8M -43.69% | 216.3M +4.35% | |
Cash and Cash Equivalents and Short-Term Investments | 103.0M -33.30% | 154.5M -8.20% | 168.3M -25.98% | 227.3M -10.86% | |
Total Current Assets | 118.4M -31.05% | 171.7M -9.73% | 190.2M -24.61% | 252.3M -6.72% | |
Accumulated Depreciation | 17.3M +27.02% | 13.6M +32.14% | 10.3M +63.91% | 6.3M +43.53% | |
Property and Plant and Equipment and Net | 17.5M -11.04% | 19.7M -16.19% | 23.5M -0.89% | 23.7M +208.87% | |
Total Long-Term Assets | 2.5M +61.03% | 1.5M +294.85% | 388,000 -52.04% | 809,000 +155.45% | |
Total Assets | 202.5M -15.44% | 239.5M -10.74% | 268.3M -6.41% | 286.7M +0.89% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 14.3M -9.56% | 15.8M -11.65% | 17.9M +15.74% | 15.4M -1.22% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 263,000 -4.01% | 274,000 -3.18% | 283,000 -78.59% | 1.3M +193.56% | |
Total Liabilities | 31.0M -6.63% | 33.2M -8.00% | 36.1M +10.47% | 32.7M +54.01% | |
Retained Earnings | -261.5M +20.58% | -216.9M +23.35% | -175.8M +27.51% | -137.9M +20.62% | |
Total Stockholders Equity | 171.5M -16.85% | 206.3M -11.16% | 232.2M -8.58% | 254.0M -3.40% | |
Total Shares Outstanding | 106.8M +1.02% | 105.7M +1.68% | 104.0M +1.53% | 102.4M +1.18% | |
Cash Flow | |||||
Cash from Operating Activities | -34.4M +24.63% | -27.6M +27.32% | -21.7M +46.70% | -14.8M +38.42% | |
Capital Expenditures | 1.8M +7.09% | 1.7M -55.38% | 3.7M -79.98% | 18.5M +381.90% | |
Cash from Investing Activities | 25.9M +274.13% | 6.9M -87.39% | 55.0M +321.50% | -24.8M -87.27% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 656,000 -68.09% | 2.1M -4.06% | 2.1M -25.81% | 2.9M -98.77% | |
Financials Ratio | |||||
Gross Margin | 81.16% -0.56% | 81.62% -7.79% | 88.51% +0.04% | 88.48% N/A | |
Operating Margin | -157.14% +18.56% | -132.54% +13.30% | -116.98% +89.24% | -61.82% N/A | |
Return on Assets | -20.20% +24.88% | -16.17% +18.32% | -13.67% +65.48% | -8.26% N/A | |
Return on Equity | -23.63% +26.17% | -18.73% +20.04% | -15.60% +71.06% | -9.12% N/A | |
Revenue Growth | -14.50% +124.98% | -6.44% -4.06% | -6.72% -121.96% | 30.59% N/A | |
Current Ratio | 8.30 -23.77% | 10.88 +2.17% | 10.65 -34.86% | 16.35 N/A | |
Cash Ratio | 1.41 -20.43% | 1.77 -32.14% | 2.60 +263.11% | 0.72 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow